Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.65 |
| ▸ | MAOB | P27338 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | SDHA | P31040 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CALML3 | P27482 | 1/20 | 0.65 |
| ▸ | F10 | P00742 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754635 | 1.00 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7838545 | 0.94 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7838549 | 0.94 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7842942 | 0.93 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7842939 | 0.93 | MAOA (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL8124484 | 0.92 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7651821 | 0.92 | MAOA (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4017727 | 0.90 | MAOA (0.66) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3754677 | 0.90 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13054904 | 0.90 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
| US-6495551-B1 | P-IMIDAZOLE-PHENYL-OXAZOLIDINES; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | SYNGENTA LIMITED (GB) | 2002-12-17 | — | — | US | disclosed |
| EP-0807112-B1 | HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6194441-B1 | GRAMNEGATIVE AND GRAMPOSITIVE BACTERIA | ZENECA LTD. (GB) | 2001-02-27 | — | — | US | disclosed |
| US-6124334-A | A BACTERICIDE TREATING INFECTIONS CAUSED BY GRAM-POSITIVE AEROBIC BACTERIA SUCH AS STAPHYLOCOCCUS, STREPTOCOCCUS AND ENTEROCOCCUS AS WELL AS ANAEROBIC ORGANISMS SUCH AS BACTEROIDES AND CLOSTRIDIUM AND MYCOBACTERIDIUM | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1034175-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES AND THEIR USE AS ANTIBIOTICS | AstraZeneca UK Limited (GB) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999028317-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES AND THEIR USE AS ANTIBIOTICS | ASTRAZENECA UK LIMITED (GB) | 1999-06-10 | — | — | WO | disclosed |
| EP-0807112-A1 | HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997031917-A9 | SUBSTITUTED PHENYLOXAZOLIDINONES AND THEIR USE AS ANTIBIOTICS | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1996023788-A1 | HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA + UPJOHN COMPANY (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | MAOA 3034/4885MAOB 2709/4885PTGS1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.